For patients with type 1 diabetes (T1D), managing blood sugar is already a constant, demanding task. What happens to that management when a patient also develops depression or anxiety? Surprisingly,
Antidepressant use in the U.S. has been climbing for years, and so has the length of time patients stay on these medications. That trend recently became a flashpoint: In May
The AI narrative in life sciences has been relentlessly optimistic. More data. Smarter models. Faster insights. And yet the actual output, therapies reaching patients, hasn’t improved at the same speed.
In the final episode of Real-World Data After Dark season 2, host Daniel Chancellor is joined by Norstella’s Kris Kaneta, Chief Product & Innovation Officer, and Ted Search, Chief Real-World
NorstellaLinQ explores how integrated real-world data and AI-powered analytics help pharmaceutical commercial teams identify high-value patients, understand prescriber behavior and uncover emerging market opportunities. By connecting claims, structured and unstructured
Norstella transforms unstructured physician notes into longitudinal, analytics-ready data that reveals insights traditional healthcare datasets miss. By combining AI, data
Traditional commercial targeting relies on historical claims and broad provider segments. NorstellaLinQ changes the equation by combining AI-curated clinical data,
Artificial intelligence is reshaping how life sciences organizations generate evidence, identify patients and make critical decisions—but only when it’s built
The P3i is the first benchmark to follow drug performance across the entire development and commercialization lifecycle. It is made
Diagnosis codes capture only a fraction of the true obesity population. Measured against recorded BMI from height and weight, the
Artificial intelligence is transforming how life sciences organizations unlock the full value of real-world data—but success depends on more than
Discover how the P3i benchmarks biopharma productivity across the drug development lifecycle.
